Praxis Precision Medicines (PRAX) Competitors $189.99 +27.28 (+16.77%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$187.82 -2.17 (-1.14%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX vs. AKRO, CRNX, MENS, NAMS, KYMR, SRRK, VKTX, MIRM, LNTH, and ADMAShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Jyong Biotech (MENS), NewAmsterdam Pharma (NAMS), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Viking Therapeutics (VKTX), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry. Praxis Precision Medicines vs. Its Competitors Akero Therapeutics Crinetics Pharmaceuticals Jyong Biotech NewAmsterdam Pharma Kymera Therapeutics Scholar Rock Viking Therapeutics Mirum Pharmaceuticals Lantheus ADMA Biologics Akero Therapeutics (NASDAQ:AKRO) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings. Do insiders & institutionals believe in AKRO or PRAX? 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 7.1% of Akero Therapeutics shares are owned by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, AKRO or PRAX? Praxis Precision Medicines has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkero TherapeuticsN/AN/A-$252.06M-$2.00-26.92Praxis Precision Medicines$8.55M467.75-$182.82M-$12.29-15.46 Do analysts recommend AKRO or PRAX? Akero Therapeutics currently has a consensus price target of $73.38, indicating a potential upside of 36.28%. Praxis Precision Medicines has a consensus price target of $218.27, indicating a potential upside of 14.89%. Given Akero Therapeutics' higher probable upside, analysts clearly believe Akero Therapeutics is more favorable than Praxis Precision Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akero Therapeutics 1 Sell rating(s) 7 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.31Praxis Precision Medicines 2 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.77 Does the media favor AKRO or PRAX? In the previous week, Praxis Precision Medicines had 31 more articles in the media than Akero Therapeutics. MarketBeat recorded 38 mentions for Praxis Precision Medicines and 7 mentions for Akero Therapeutics. Praxis Precision Medicines' average media sentiment score of 0.42 beat Akero Therapeutics' score of -0.08 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akero Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 7 Very Positive mention(s) 12 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Is AKRO or PRAX more profitable? Akero Therapeutics' return on equity of -15.84% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Akero TherapeuticsN/A -15.84% -14.59% Praxis Precision Medicines N/A -60.07%-54.84% Which has more risk & volatility, AKRO or PRAX? Akero Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.62, indicating that its stock price is 162% more volatile than the S&P 500. SummaryPraxis Precision Medicines beats Akero Therapeutics on 10 of the 15 factors compared between the two stocks. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.00B$3.44B$6.19B$10.55BDividend YieldN/A2.28%5.70%4.81%P/E Ratio-15.4623.1685.6227.13Price / Sales467.75499.63615.49134.47Price / CashN/A46.9237.1060.81Price / Book7.9510.4112.236.52Net Income-$182.82M-$52.77M$3.33B$276.93M7 Day Performance256.72%2.31%1.17%1.93%1 Month Performance350.00%12.59%6.85%2.19%1 Year Performance159.55%11.18%58.93%34.62% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines1.8652 of 5 stars$189.99+16.8%$218.27+14.9%+159.5%$4.00B$8.55M-15.46110Trending NewsAnalyst ForecastGap UpHigh Trading VolumeAKROAkero Therapeutics3.5527 of 5 stars$53.66-0.4%$73.38+36.7%+72.4%$4.31BN/A-26.8330Insider TradeCRNXCrinetics Pharmaceuticals4.3745 of 5 stars$44.43-1.1%$74.45+67.6%-29.6%$4.23B$1.04M-10.81210Positive NewsMENSJyong BiotechN/A$55.70+0.8%N/AN/A$4.20BN/A0.0031Gap DownNAMSNewAmsterdam Pharma2.9656 of 5 stars$37.15+0.3%$42.00+13.1%+89.0%$4.17B$45.56M-22.934News CoverageAnalyst ForecastHigh Trading VolumeKYMRKymera Therapeutics1.0084 of 5 stars$59.89+4.7%$61.26+2.3%+28.9%$4.09B$47.07M-17.26170Analyst ForecastInsider TradeSRRKScholar Rock4.4717 of 5 stars$34.28-13.1%$48.60+41.8%-8.5%$3.79B$33.19M-11.78140Gap DownHigh Trading VolumeVKTXViking Therapeutics3.8797 of 5 stars$33.91+1.0%$86.42+154.8%-49.0%$3.77BN/A-22.1620News CoverageUpcoming EarningsMIRMMirum Pharmaceuticals3.5885 of 5 stars$72.17-0.7%$76.50+6.0%+86.3%$3.65B$336.89M-59.64140Trending NewsAnalyst ForecastAnalyst RevisionLNTHLantheus4.5327 of 5 stars$54.59+2.0%$74.50+36.5%-52.4%$3.64B$1.53B14.52700Trending NewsAnalyst RevisionADMAADMA Biologics3.6341 of 5 stars$14.55+0.1%$27.67+90.1%-9.0%$3.47B$426.45M16.92530 Related Companies and Tools Related Companies Akero Therapeutics Competitors Crinetics Pharmaceuticals Competitors Jyong Biotech Competitors NewAmsterdam Pharma Competitors Kymera Therapeutics Competitors Scholar Rock Competitors Viking Therapeutics Competitors Mirum Pharmaceuticals Competitors Lantheus Competitors ADMA Biologics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAX) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRAX Stock Alerts